Optimizing liposomes for delivery of chemotherapeutic agents to solid tumors.

There are many potential barriers to the effective delivery of a drug in its active form to solid tumors. Most small-molecule chemotherapeutic agents have a large volume of distribution on i.v. administration ([Speth et al., 1988][1]; [Chabner and Longo, 1996][2]). The result of this is often a

• Publication year

  1999

• Venue

  Pharmacological Reviews

• Publication date

  1999-12-01

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1016/s0031-6997(24)01426-1PMID 10581328
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Tumor angiogenesis

  2020cited by this paper
• Clinical Efficacy and Prospects for Use of Pegylated Liposomal Doxorubicin in the Treatment of Ovarian and Breast Cancers

  2012cited by this paper
• Safety Aspects of Pegylated Liposomal Doxorubicin in Patients with Cancer

  2012cited by this paper
• In vivo antitumor activity of cis-bis-neodecanoato-trans- R,R-l,2-diaminocyclohexane platinum(II) formulated in long-circulating liposomes

  2009cited by this paper
• Studies on the myelosuppressive activity of doxorubicin entrapped in liposomes

  2004cited by this paper
• Phase I and pharmacokinetic trial of liposome-encapsulated doxorubicin

  2004cited by this paper
• Identification of vesicle properties that enhance the antitumour activity of liposomal vincristine against murine L1210 leukemia

  2004cited by this paper
• Transfer of liposomal drug carriers from the blood to the peritoneal cavity of normal and ascitic tumor-bearing mice

  2004cited by this paper
• Characterization of organ-specific immunoliposomes for delivery of 3′,5′-O-dipalmitoyl-5-fluoro-2′-deoxyuridine in a mouse lung-metastasis model

  2004cited by this paper
• Analysis of the effect of liposome encapsulation on the vesicant properties, acute and cardiac toxicities, and antitumor efficacy of doxorubicin

  2004cited by this paper
• Cancer Chemotherapy and Biotherapy: Principles and Practice

  2001cited by this paper
• Comparative pharmacokinetics, tissue distribution, and therapeutic effectiveness of cisplatin encapsulated in long-circulating, pegylated liposomes (SPI-077) in tumor-bearing mice

  1999cited by this paper
• Vessel cooption, regression, and growth in tumors mediated by angiopoietins and VEGF.

  1999cited by this paper
• Anti‐HER2 Immunoliposomes for Targeted Drug Delivery

  1999cited by this paper
• Reduction of the cardiotoxicity of doxorubicin in rabbits and dogs by encapsulation in long-circulating, pegylated liposomes.

  1999cited by this paper
• Phase I study of liposomal vincristine.

  1999cited by this paper
• Phase II trial of liposome-encapsulated doxorubicin, cyclophosphamide, and fluorouracil as first-line therapy in patients with metastatic breast cancer.

  1999influential reference
• Relationship of dose intensity to the induction of palmar-plantar erythrodysesthia by pegylated liposomal doxorubicin in dogs

  1999cited by this paper
• Pharmacokinetic behavior of vincristine sulfate following administration of vincristine sulfate liposome injection

  1998influential reference
• Cationic Liposomes Coated with Polyethylene Glycol As Carriers for Oligonucleotides*

  1998cited by this paper
• In vitro and in vivo targeting of immunoliposomal doxorubicin to human B-cell lymphoma.

  1998cited by this paper
• Doxorubicin entrapped in sterically stabilized liposomes: effects on bacterial blood clearance capacity of the mononuclear phagocyte system.

  1998influential reference
• The value of dose intensification of standard chemotherapy for advanced breast cancer using colony-stimulating factors alone.

  1998cited by this paper
• Regulation of transport pathways in tumor vessels: role of tumor type and microenvironment.

  1998cited by this paper
• Comparison of different hydrophobic anchors conjugated to poly(ethylene glycol): effects on the pharmacokinetics of liposomal vincristine.

  1998cited by this paper
• CHAPTER 7.1 – Design of liposome-based drug carriers: From basic research to application as approved drugs

  1998cited by this paper
• Copolymers of N‐isopropylacrylamide can trigger pH sensitivity to stable liposomes

  1998cited by this paper
• Pegylated-liposomal doxorubicin versus doxorubicin, bleomycin, and vincristine in the treatment of AIDS-related Kaposi's sarcoma: results of a randomized phase III clinical trial.

  1998cited by this paper
• Comparative study of the antitumor activity of free doxorubicin and polyethylene glycol-coated liposomal doxorubicin in a mouse lymphoma model.

  1998cited by this paper
• Controlling the Drug Delivery Attributes of Lipid-Based Drug Formulations

  1998cited by this paper
• Encapsulation of the topoisomerase I inhibitor GL147211C in pegylated (STEALTH) liposomes: pharmacokinetics and antitumor activity in HT29 colon tumor xenografts.

  1998cited by this paper
• CHAPTER 4.2 – Designing therapeutically optimized liposomal anticancer delivery systems: Lessons from conventional liposomes

  1998cited by this paper
• Randomized comparative trial of pegylated liposomal doxorubicin versus bleomycin and vincristine in the treatment of AIDS-related Kaposi's sarcoma. International Pegylated Liposomal Doxorubicin Study Group.

  1998cited by this paper
• Comparative intravenous toxicity of cisplatin solution and cisplatin encapsulated in long-circulating, pegylated liposomes in cynomolgus monkeys.

  1998cited by this paper
• Effect of Lipid Dose on the Redistribution and Blood Pool Clearance Kinetics of Peg-Modified Technetium-Labeled Lipid Vesicles

  1998cited by this paper
• CHAPTER 8.3 – The Liposome Company: Lipid-based pharmaceuticals in clinical development

  1998cited by this paper
• CHAPTER 8.1 – Clinical trials of liposomes as carriers of chemotherapeutic agents: Synopsis and perspective

  1998cited by this paper
• CHAPTER 4.4 – Cellular distribution of DOXIL® within selected tissues, assessed by confocal laser scanning microscopy

  1998cited by this paper
• The influence of the route of administration and liposome composition on the potential of liposomes to protect tissue against local toxicity of two antitumor drugs.

  1998influential reference
• Inhibition of Tracheal Vascular Extravasation by Liposome-Encapsulated Albuterol in Rats

  1998cited by this paper
• Hand‐foot syndrome following prolonged infusion of high doses of vinorelbine

  1998cited by this paper
• CHAPTER 8.4 – Unilamellar liposomes for anticancer and antifungal therapy

  1998cited by this paper
• Liposomal drug formulations. Rationale for development and what we can expect for the future.

  1998cited by this paper
• Efficacy of pyridoxine to ameliorate the cutaneous toxicity associated with doxorubicin containing pegylated (Stealth) liposomes: a randomized, double-blind clinical trial using a canine model.

  1998cited by this paper
• Cost-effectiveness analysis comparing liposomal anthracyclines in the treatment of AIDS-related Kaposi's sarcoma.

  1998cited by this paper
• Sterically Stabilized Immunoliposomes: Formulations for Delivery of Drugs and Genes to Tumor Cells in Vivo

  1998cited by this paper
• CHAPTER 4.6 – Targeted sterically stabilized liposomal drug delivery

  1998cited by this paper
• Triggerable liposomal fusion by enzyme cleavage of a novel peptide-lipid conjugate.

  1998cited by this paper
• Commentary: Rantosomes and Ravosomes

  1998cited by this paper
• CHAPTER 8.2 – Clinical pharmacology and antitumor efficacy of DOXIL (pegylated liposomal doxorubicin)

  1998influential reference
• Targeting of Drugs to Solid Tumors Using Anti-Her2 Immunoliposomes

  1998cited by this paper
• Ligand-targeted liposomes.

  1998cited by this paper
• CHAPTER 4.7 – Targeting of sterically stabilized liposomes to cancers overexpressing HER2/neu proto-oncogene

  1998cited by this paper
• The use of cardiac biopsy to demonstrate reduced cardiotoxicity in AIDS Kaposi's sarcoma patients treated with pegylated liposomal doxorubicin.

  1998cited by this paper
• Effect of host microenvironment on the microcirculation of human colon adenocarcinoma.

  1997cited by this paper
• Polyethylene glycol-liposomal doxorubicin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in the management of AIDS-related Kaposi's sarcoma.

  1997cited by this paper
• Polyethylene glycol-coated (pegylated) liposomal doxorubicin. Rationale for use in solid tumours.

  1997cited by this paper
• Phase II study of liposomal doxorubicin in refractory ovarian cancer: antitumor activity and toxicity modification by liposomal encapsulation.

  1997cited by this paper
• Immunoliposomes for cancer treatment.

  1997influential reference
• Activity of paclitaxel liposome formulations against human ovarian tumor xenografts

  1997cited by this paper
• The role of immunoproteins in the survival of liposomes in the circulation.

  1997cited by this paper
• Accumulation of liposomal lipid and encapsulated doxorubicin in murine Lewis lung carcinoma: the lack of beneficial effects by coating liposomes with poly(ethylene glycol).

  1997cited by this paper
• Phase I trial of dose-intense liposome-encapsulated doxorubicin in patients with advanced sarcoma.

  1997influential reference
• Role of delivery vehicles for photosensitizers in the photodynamic therapy of tumours.

  1997cited by this paper
• Liposomal doxorubicin circumvents PSC 833-free drug interactions, resulting in effective therapy of multidrug-resistant solid tumors.

  1997cited by this paper
• Intratumor distribution of doxorubicin following i.v. administration of drug encapsulated in egg phosphatidylcholine/cholesterol liposomes

  1997cited by this paper
• Simultaneous Measurement of Liposome Extravasation and Content Release in Tumors

  1997cited by this paper
• Population pharmacokinetics and pharmacodynamics of pegylated‐liposomal doxorubicin in patients with AIDS‐related Kaposi's sarcoma

  1997cited by this paper
• Oligonucleotide Pharmacology and Formulation: G3139 Anti-BCL2 Phosphorothioate In Stealth® Liposomes and Gel Implants

  1997cited by this paper
• Treatment of advanced breast cancer with sterically stabilized liposomal doxorubicin: results of a multicenter phase II trial.

  1997influential reference
• Paroxysmal Headache Caused by Colloid Cyst of the Third Ventricle: Case Report and Review of the Literature

  1997cited by this paper
• The role of tumor-associated macrophages in the delivery of liposomal doxorubicin to solid murine fibrosarcoma tumors.

  1997cited by this paper
• Poly(ethylene glycol)‐lipid conjugates inhibit phospholipase C‐induced lipid hydrolysis, liposome aggregation and fusion through independent mechanisms

  1997cited by this paper
• Influence of drug release characteristics on the therapeutic activity of liposomal mitoxantrone.

  1997cited by this paper
• Targeting of Liposomes to Solid Tumors: The Case of Sterically Stabilized Anti-Her2 Immunoliposomes

  1997cited by this paper
• Haematological toxicities associated with dose-intensive chemotherapy, the role for and use of recombinant growth factors.

  1997cited by this paper
• Liposomal daunorubicin is not recommended in patients with less than advanced HIV-related Kaposi's sarcoma.

  1997cited by this paper
• Plasma clearance, biodistribution and therapeutic properties of mitoxantrone encapsulated in conventional and sterically stabilized liposomes after intravenous administration in BDF1 mice.

  1997influential reference
• Efficacy of pegylated-liposomal doxorubicin in the treatment of AIDS-related Kaposi's sarcoma after failure of standard chemotherapy.

  1997cited by this paper
• Tumour uptake of doxorubicin in polyethylene glycol-coated liposomes and therapeutic effect against a xenografted human pancreatic carcinoma.

  1997cited by this paper
• Antibody-targeted liposomes: prospects and problems

  1997cited by this paper
• LIPOSOMAL DAUNORUBICIN IS NOT RECOMMENDED IN PATIENTS WITH LESS THAN ADVANCED HIV-RELATED KAPOSI'S SARCOMA

  1997cited by this paper
• Toxicity of doxorubicin entrapped within long-circulating liposomes

  1997cited by this paper
• Non-small-cell lung carcinoma tumor growth without morphological evidence of neo-angiogenesis.

  1997cited by this paper
• A Comparative Review of Colony-Stimulating Factors

  1997cited by this paper
• Sensitivity to camptothecin of human breast carcinoma and normal endothelial cells

  1997cited by this paper
• Long-circulating liposomes for drug delivery in cancer therapy: a review of biodistribution studies in tumor-bearing animals

  1997cited by this paper
• The pharmacology of ergotamine and dihydroergotamine.

  1997cited by this paper
• Influence of pH gradients on the transbilayer transport of drugs, lipids, peptides and metal ions into large unilamellar vesicles.

  1997cited by this paper
• Sterically stabilized anti-HER2 immunoliposomes: design and targeting to human breast cancer cells in vitro.

  1997cited by this paper
• Enhancement of the in vivo circulation lifetime of L-alpha-distearoylphosphatidylcholine liposomes: importance of liposomal aggregation versus complement opsonization.

  1997cited by this paper
• Influence of cholesterol on the association of plasma proteins with liposomes.

  1996cited by this paper
• Doxorubicin Encapsulated in Liposomes Containing Surface‐Bound Polyethylene Glycol: Pharmacokinetics, Tumor Localization, and Safety in Patients with AIDS‐Related Kaposi's Sarcoma

  1996cited by this paper
• Thermosensitive liposomes: extravasation and release of contents in tumor microvascular networks.

  1996cited by this paper
• Liposomes with detachable polymer coating: destabilization and fusion of dioleoylphosphatidylethanolamine vesicles triggered by cleavage of surface‐grafted poly(ethylene glycol)

  1996cited by this paper
• Poly(ethylene glycol)--lipid conjugates regulate the calcium-induced fusion of liposomes composed of phosphatidylethanolamine and phosphatidylserine.

  1996cited by this paper
• Hyperthermia enhances tumor uptake and antitumor efficacy of thermostable liposomal daunorubicin in a rat solid tumor.

  1996cited by this paper
• Liposome longevity and stability in circulation: effects on the in vivo delivery to tumors and therapeutic efficacy of encapsulated anthracyclines.

  1996influential reference
• Cholesterol-induced interfacial area condensations of galactosylceramides and sphingomyelins with identical acyl chains.

  1996cited by this paper
• Targeting of stealth liposomes to erbB-2 (Her/2) receptor: in vitro and in vivo studies.

  1996influential reference

• Modeling lipid nanoparticle transport in extracellular matrix: Effects of particle size and rigidity

  2026cites this paper
• Liposome-engineered therapeutics: A promising frontier in ovarian cancer treatment.

  2025cites this paper
• Pegylated liposomal doxorubicin does not affect cardiac function in patients treated for gynecologic malignancies

  2025cites this paper
• Advancements in Liposomal Nanomedicines: Innovative Formulations, Therapeutic Applications, and Future Directions in Precision Medicine

  2025cites this paper
• Nanotechnology-mediated precision drug delivery strategies for breast cancer treatment.

  2025cites this paper
• New insights into Notch signaling as a crucial pathway of pancreatic cancer stem cell behavior by chrysin-polylactic acid-based nanocomposite

  2025cites this paper
• Comprehensive analysis of structural, dynamic, and thermodynamic properties of oil-in-water microemulsions coated with polyethylene oxide-decorated telechelic polymers and stabilized by non-ionic surfactants

  2025cites this paper
• Nanocarrier-based Drug Delivery Systems to Enhance Antimicrobial Photodynamic Therapy in Dental Applications: A Review

  2025cites this paper
• Descriptive Review on Liposomal Drug Delivery System

  2024cites this paper
• DOTAP Modified Formulations of Aminoacid Based Cationic Liposomes for Improved Gene Delivery and Cell Viability

  2024cites this paper
• Development and in vitro characterization of new carnosine-loaded liposomal formulations

  2024cites this paper
• The journey of nanoparticles in the abdominal cavity: Exploring their in vivo fate and impact factors.

  2024cites this paper
• Bio-soft matter derived from traditional Chinese medicine: Characterizations of hierarchical structure, assembly mechanism, and beyond

  2024cites this paper
• Dual Centrifugation‐Based Screening for pH‐Responsive Liposomes

  2024cites this paper
• Cisplatin-based Liposomal Nanocarriers for Drug Delivery in Lung Cancer Therapy: Recent Progress and Future Outlooks.

  2024cites this paper
• Hypolipidemic and antioxidant effect of liposomal Rosuvastatin in vivo

  2024cites this paper
• Unravelling the in vivo dynamics of liposomes: Insights into biodistribution and cellular membrane interactions.

  2024cites this paper
• Microfluidics in drug delivery: review of methods and applications

  2023cites this paper
• Interaction of Neutral and Protonated Tamoxifen with the DPPC Lipid Bilayer using Molecular Dynamics Simulation.

  2023cites this paper
• Cerasome Versus Liposome: A Comparative Pharmacokinetic Analysis Following Intravenous Administration into Rats

  2023cites this paper
• Effect of phospholipid head group on ultrasound-triggered drug release and cellular uptake of immunoliposomes

  2023cites this paper
• Gold cluster encapsulated liposomes: theranostic agent with stimulus triggered release capability

  2023cites this paper
• Liposomes and phytosomes: Nanocarrier systems and their applications for the delivery of phytoconstituents

  2023cites this paper
• Nanoengineered approaches to improve the efficacy of targeted drug delivery for the treatment of malignancy: a comprehensive review

  2023cites this paper
• Challenges and future directions for next-generation biomedical polymersomes

  2023cites this paper
• Nanoparticle targeting of mechanically modulated glycocalyx

  2023cites this paper
• Ultrasound boosts doxorubicin efficacy against sensitive and resistant ovarian cancer cells.

  2023cites this paper
• Population pharmacokinetic analysis of TQ-B3203 following intravenous administration of TQ-B3203 liposome injection in Chinese patients with advanced solid tumors

  2023cites this paper
• Liposomes in Cancer Therapy: How Did We Start and Where Are We Now

  2023cites this paper
• Engineering Escherichia coli Nissle 1917 as a microbial chassis for therapeutic and industrial applications.

  2023cites this paper
• Vacuum foam drying of docetaxel mixed micelles for improved stability and ovarian cancer treatment

  2023cites this paper
• Liposomes for drug delivery: review of vesicular composition, factors affecting drug release and drug loading in liposomes

  2023cites this paper
• Predicting intratumoral fluid pressure and liposome accumulation using physics informed deep learning

  2023cites this paper
• Tools shaping drug discovery and development.

  2022cites this paper
• Determination of the Effectiveness of a Novel Liposome Formulation of Proteasome Inhibitors

  2022cites this paper
• Effect of Hydrophile-Lipophile Balance of the Linker in Gal/GalNAc Ligands on High-Affinity Binding of Galactosylated Liposomes by the Asialoglycoprotein Receptor.

  2022cites this paper
• Doxorubicin-Loaded Multivesicular Liposomes (DepoFoam) as a Sustained Release Carrier Intended for Locoregional Delivery in Cancer Treatment: Development, Characterization, and Cytotoxicity Evaluation

  2022cites this paper
• Critical appraisal of clinical guidelines for prevention and management of doxorubicin-induced cardiotoxicity

  2022cites this paper
• Ameliorative impacts of polymeric and metallic nanoparticles on cisplatin-induced nephrotoxicity: a 2011–2022 review

  2022cites this paper
• Hybrid Ultrasound-Activated Nanoparticles Based on Graphene Quantum Dots for Cancer Treatment.

  2022cites this paper
• Novel Implications of Nanoparticle-Enhanced Radiotherapy and Brachytherapy: Z-Effect and Tumor Hypoxia

  2022cites this paper
• Antitumor Immunotherapy of Sialic Acid and/or GM1 Modified Coenzyme Q10 Submicron Emulsion

  2022cites this paper
• The Therapeutic Potential of Chemo/Thermotherapy with Magnetoliposomes for Cancer Treatment

  2022cites this paper
• Nano-Based Approved Pharmaceuticals for Cancer Treatment: Present and Future Challenges

  2022cites this paper
• Harnessing Ultrasound for Targeting Drug Delivery to the Brain and Breaching the Blood–Brain Tumour Barrier

  2022cites this paper
• Combinatorial approaches of nanotherapeutics for inflammatory pathway targeted therapy of prostate cancer.

  2022cites this paper
• Re-directing nanomedicines to the spleen: A potential technology for peripheral immunomodulation.

  2022cites this paper
• Effect of Particle Carriers for Intraperitoneal Drug Delivery on the Course of Ovarian Cancer and Its Immune Microenvironment in a Mouse Model

  2022cites this paper
• Clinical application and future direction of liposomal assisted drug delivery system

  2022cites this paper
• Capillary electrophoresis-mass spectrometry in pharmaceutical and biomedical analyses.

  2022cites this paper
• Preclinical evaluations of Norcantharidin liposome and emulsion hybrid delivery system with improved encapsulation efficiency and enhanced antitumor activity

  2022cites this paper
• The combination of MnO2@Lipo-coated gefitinib and bevacizumab inhibits the development of non-small cell lung cancer

  2022cites this paper
• Progress and Viewpoints of Multifunctional Composite Nanomaterials for Glioblastoma Theranostics

  2022cites this paper
• Recent Advances in the Biomedical Applications of Functionalized Nanogels

  2022cites this paper
• Pharmacokinetics and in vivo evaluation of nanoparticles

  2022cites this paper
• A mucoadhesive patch loaded with freeze-dried liposomes for the local treatment of oral tumors

  2022cites this paper
• Strategies to assemble therapeutic and imaging molecules into inorganic nanocarriers

  2022cites this paper
• Structure‐Based Varieties of Polymeric Nanocarriers and Influences of Their Physicochemical Properties on Drug Delivery Profiles

  2022cites this paper
• Nanomedicine Tactics in Cancer Treatment: Challenge and Hope.

  2022cites this paper
• Development of disulfide-stabilized Fabs for targeting of antibody-directed nanotherapeutics

  2022cites this paper
• Sequential administration of PEG-Span 80 niosome enhances anti-tumor effect of doxorubicin-containing PEG liposome.

  2021cites this paper
• Inducible Tertiary Lymphoid Structures: Promise and Challenges for Translating a New Class of Immunotherapy

  2021cites this paper
• Effect of hydrophobically modified PEO polymers (PEO-dodecyl) on oil/water microemulsion properties: in vitro and in silico investigations

  2021cites this paper
• Chitosan-covered liposomes as a promising drug transporter: nanoscale investigations

  2021cites this paper
• Factors affecting the pharmacokinetics of the liposomal drugs

  2021cites this paper
• Correction: Effect of hydrophobically modified PEO polymers (PEO-dodecyl) on oil/water microemulsion properties: in vitro and in silico investigations

  2021cites this paper
• Recent advancements, developments, and regulatory issues in nanomedicine

  2021cites this paper
• Emerging Applications of Nanotechnology in Healthcare Systems: Grand Challenges and Perspectives

  2021cites this paper
• Cytostatic and Cytotoxic Effects of Hollow-Shell Mesoporous Silica Nanoparticles Containing Magnetic Iron Oxide

  2021cites this paper
• Highly Toxic Nanomaterials for Cancer Treatment

  2021cites this paper
• Nano-pharmacokinetics: interface of physics, chemistry and biology

  2021cites this paper
• An Insight into Nanosomes: Potential Nanopharmaceutical Delivery System

  2021cites this paper
• Current Status of Brain Tumor in the Kingdom of Saudi Arabia and Application of Nanobiotechnology for Its Treatment: A Comprehensive Review

  2021cites this paper
• Liposomal Nanomedicine: Applications for Drug Delivery in Cancer Therapy

  2021cites this paper
• Molecular Perspective of Nanoparticle Mediated Therapeutic Targeting in Breast Cancer: An Odyssey of Endoplasmic Reticulum Unfolded Protein Response (UPRER) and Beyond

  2021cites this paper
• AN OVERVIEW ON BRAIN TARGETED DRUG DELIVERY SYSTEM

  2021cites this paper
• Modeling of Anti-Cancer Drug Release Kinetics From Liposomes and Micelles: A Review

  2021cites this paper
• Development and Optimization of Irinotecan-Loaded PCL Nanoparticles and Their Cytotoxicity against Primary High-Grade Glioma Cells

  2021cites this paper
• In vitro evaluation of polymeric nanoparticles with a fluorine core for drug delivery triggered by focused ultrasound.

  2021cites this paper
• Influence of Dose on Neutrophil-Mediated Delivery of Nanoparticles for Tumor-Targeting Therapy Strategies

  2021cites this paper
• Paclitaxel loading in cationic liposome vectors is enhanced by replacement of oleoyl with linoleoyl tails with distinct lipid shapes

  2021cites this paper
• Therapeutic Effect of Murine Bone Marrow-Derived Mesenchymal Stromal/Stem Cells and Human Placental Extract on Testicular Toxicity Resulting from Doxorubicin in Rats

  2021cites this paper
• Production of PEG-coated liposomes using a continuous supercritical assisted process

  2021cites this paper
• Modeling of Drug Release Kinetics from Stimuli-Responsive Micelles and Liposomes: A review

  2021cites this paper
• Recent Advances in the Local Drug Delivery Systems for Improvement of Anticancer Therapy.

  2021cites this paper
• Cardiotoxicity: A Major Setback in Childhood Leukemia Treatment

  2021cites this paper
• Antennapedia‐derived positively‐charged peptide faces multiple problems upon their usage as targeting ligand for liposomal doxorubicin

  2021cites this paper
• The Polar Lipid Fraction E from Sulfolobus acidocaldarius Can Be Used as Liposomal Drug Stabilizing Agents to Reduce the Leakage of the Antivascular Drug Combretastatin A4 Disodium Phosphate from Tetraether/Diester Hybrid Archaeosomes

  2021cites this paper
• Real-time particle-by-particle detection of erythrocyte-camouflaged microsensor with extended circulation time in the bloodstream

  2020cites this paper
• Polymeric Nanoparticles for the Treatment of Malignant Gliomas

  2020cites this paper
• Immunological and Toxicological Considerations for the Design of Liposomes

  2020cites this paper
• Gold nanoparticles in cancer diagnosis and therapy

  2020cites this paper
• Grand challenges in nanomedicine.

  2020cites this paper
• A Current Nanoparticles approaches in Nose to Brain Drug Delivery and Anticancer Therapy - A Review.

  2020cites this paper
• Investigation of the programmed cell death by encapsulated cytoskeleton drug liposomes using a microfluidic platform

  2020cites this paper
• Recent advances in inhalable liposomes for treatment of pulmonary diseases: Concept to clinical stance

  2020cites this paper
• A futuristic insight into a “nano-doctor”: A clinical review on medical diagnosis and devices using nanotechnology

  2020cites this paper
• The evaluation of lymph node cell proliferation response by liposomes loaded with major histocompatibility complex class II binding aquaporin 4 antigen peptide.

  2020cites this paper
• Is tumor cell specificity distinct from tumor selectivity in vivo? A quantitative NIR molecular imaging analysis of nanoliposome targeting

  2020cites this paper
• Lipid-Based Tumor-targeted Systems

  2020cites this paper